Senthil Rajappa

Dr. Senthil Rajappa


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2019 in Advances in Therapy
Verified
Journal Article
Closed access
PDF file
SRSenthil Rajappa
Senthil Rajappa
MKM. Vamshi Krishna
M. Vamshi Krishna
PNPrasad Narayanan
Prasad Narayanan

29 January 2019 in Advances in Therapy
Verified
Journal Article
Closed access
PDF file
SRSenthil Rajappa
Senthil Rajappa
SSSanjiv Sharma
Sanjiv Sharma
KPKrishna Prasad
Krishna Prasad

12 January 2022 in Targeted Oncology
Verified
Journal Article
Open access
PDF file
HTHai-Yan Tu
Hai-Yan Tu
JFJi-feng Feng
Ji-feng Feng
MSMeiqi Shi
Meiqi Shi
JZJUN ZHAO
JUN ZHAO
YWYuyan Wang
Yuyan Wang
YWYI-LONG WU
YI-LONG WU
Background Afatinib has been shown as a suitable option for the treatment of epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC) in randomized controlled trials. However, patients treated in real-world clinical practice, including elderly patients, and those with brain metastases or poor Eastern Cooperative Oncology Group (ECOG) performance statuses, are often excluded from these studies. Objective To report the final results, with a particular focus on patients enrolled in China, from a prospective phase IIIb, “near real-world” study of afatinib in tyrosine kinase inhibitor (TKI)-naïve Asian patients with EGFRm+ NSCLC. Patients and Methods NCT01953913 was conducted at 34 centers across Asia. Entry criteria were broad to reflect real-world settings. Patients received afatinib 40 mg/day until tumor progression, lack of clinical benefit, or poor tolerability. Assessments included safety, time to symptomatic progression (TTSP), and progression-free survival (PFS). Results 541 patients were treated, of whom 412 were enrolled in China. Dose reductions were implemented in 28.7% of patients overall, and 17.7% of patients from China. Safety findings were consistent with phase III studies of afatinib. Median TTSP in all patients was 14.0 months (95% CI 12.9–15.9), and median PFS was 12.1 months (95% CI 11.0–13.6). Median TTSP (13.8 months, 95% CI 12.7–16.1) and PFS (11.4 months, 95% CI 10.9–13.7) were similar in patients from China to the overall population. Among patients from China who had dose reductions, TTSP was numerically longer than in those who did not (16.4 vs. 13.8 months; P = 0.0703), while PFS was significantly longer (13.9 vs. 11.1 months; P = 0.0275). Among patients from China with brain metastases, TTSP was numerically shorter than in those without (11.0 vs. 14.4 months; P = 0.0869), whereas PFS was significantly shorter (9.2 vs. 12.9 months; P = 0.0075). Conclusions Safety data for afatinib when used in a “near real-world” setting in patients with EGFRm+ NSCLC was consistent with the known safety profile of afatinib. Supporting efficacy data of afatinib were provided in all patients, and in those enrolled in China. Tolerability-guided afatinib dose reduction allowed patients to remain on treatment and continue to experience clinical benefit. Trial Registration Number and Date of Registration NCT01953913 (1 October 2013).

1 July 2022 in Cancer Research, Statistics, and Treatment
Verified
Journal Article
Open access
SRSenthil Rajappa
Senthil Rajappa
RPRakesh Pinninti
Rakesh Pinninti

2 August 2024 in Cancer Epidemiology
Verified
Journal Article
Closed access
VNVanita Ann Noronha
Vanita Ann Noronha
ARAbhijith Rajaram Rao
Abhijith Rajaram Rao
APAnupa Pillai
Anupa Pillai
AKAnita Kumar
Anita Kumar
SRSenthil Rajappa
Senthil Rajappa
KPKumar Prabhash
Kumar Prabhash

11 October 2023 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
MKMridula Krishnan
Mridula Krishnan
PAPriyal Agarwal
Priyal Agarwal
RPRakesh Pinninti
Rakesh Pinninti
SRSenthil Rajappa
Senthil Rajappa